Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip J Clements

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
BMJ Open Gastroenterology|August 2, 2017
Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohortsElizabeth R Volkmann, Anna-Maria Hoffmann-Vold, Yu-Ling Chang, et al.
Clinical and Experimental Rheumatology|May 19, 2011
Quality indicator set for systemic sclerosisDinesh Khanna, Otylia Kowal-Bielecka, Puja P Khanna, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 25, 2019
Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18Elizabeth R Volkmann, Donald P Tashkin, Masataka Kuwana, et al.
Annals of the Rheumatic Diseases|November 10, 2018
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohortsElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
Journal of Scleroderma and Related Disorders|May 19, 2017
Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosisDinesh Khanna, Daniel E Furst, Philip J Clements, et al.
Annals of the Rheumatic Diseases|May 9, 2007
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosisPhilip J Clements, Michael D Roth, Robert Elashoff, et al.
The Journal of Rheumatology|May 4, 2005
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trialDinesh Khanna, Daniel E Furst, Philip J Clements, et al.
Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.
Journal of Scleroderma and Related Disorders|March 26, 2019
An Interim Report of the Scleroderma Clinical Trials Consortium Working GroupsMurray Baron, Bashar Kahaleh, Elana J Bernstein, et al.
Arthritis and Rheumatism|November 13, 2002
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trialPaul J DeMarco, Michael H Weisman, James R Seibold, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
BMJ Open Gastroenterology|August 2, 2017
Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohortsElizabeth R Volkmann, Anna-Maria Hoffmann-Vold, Yu-Ling Chang, et al.
Clinical and Experimental Rheumatology|May 19, 2011
Quality indicator set for systemic sclerosisDinesh Khanna, Otylia Kowal-Bielecka, Puja P Khanna, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 25, 2019
Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18Elizabeth R Volkmann, Donald P Tashkin, Masataka Kuwana, et al.
Annals of the Rheumatic Diseases|November 10, 2018
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohortsElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
Journal of Scleroderma and Related Disorders|May 19, 2017
Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosisDinesh Khanna, Daniel E Furst, Philip J Clements, et al.
Annals of the Rheumatic Diseases|May 9, 2007
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosisPhilip J Clements, Michael D Roth, Robert Elashoff, et al.
The Journal of Rheumatology|May 4, 2005
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trialDinesh Khanna, Daniel E Furst, Philip J Clements, et al.
Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.
Journal of Scleroderma and Related Disorders|March 26, 2019
An Interim Report of the Scleroderma Clinical Trials Consortium Working GroupsMurray Baron, Bashar Kahaleh, Elana J Bernstein, et al.
Arthritis and Rheumatism|November 13, 2002
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trialPaul J DeMarco, Michael H Weisman, James R Seibold, et al.
Pageof 10